Site-selective protein conjugation at histidine by Peciak, K et al.
Chemical
Science
EDGE ARTICLE
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
9 
O
ct
ob
er
 2
01
8.
 D
ow
nl
oa
de
d 
on
 1
/1
7/
20
19
 9
:2
4:
01
 A
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
View Journal  | View IssueSite-selective proaUCL School of Pharmacy, University Co
London, WC1N 1AX, UK. E-mail: steve.brocc
bAbzena, Babraham Research Campus, Babr
† Electronic supplementary informa
10.1039/c8sc03355b
‡ Current address: Ipsen Biopharm Lim
Estate, Wrexham, LL13 9UF, UK.
§ Current address: Bio-LogicIP, 1 Westbou
{ Current address: Lonza Biologics, 228 B
Cite this: Chem. Sci., 2019, 10, 427
All publication charges for this article
have been paid for by the Royal Society
of Chemistry
Received 28th July 2018
Accepted 9th October 2018
DOI: 10.1039/c8sc03355b
rsc.li/chemical-science
This journal is © The Royal Society of Ctein conjugation at histidine†
Karolina Peciak,‡ab Emmanuelle Laurine,§b Rita Tommasi,{b Ji-won Choib
and Steve Brocchini *a
Site-selective conjugation generally requires both (i) molecular engineering of the protein of interest to
introduce a conjugation site at a deﬁned location and (ii) a site-speciﬁc conjugation technology. Three
N-terminal interferon a2-a (IFN) variants with truncated histidine tags were prepared and conjugation
was examined using a bis-alkylation reagent, PEG(10kDa)-mono-sulfone 3. A histidine tag comprised of
two histidines separated by a glycine (His2-tag) underwent PEGylation. Two more IFN variants were then
prepared with the His2-tag engineered at diﬀerent locations in IFN. Another IFN variant was prepared
with the His-tag introduced in an a-helix, and required three contiguous histidines to ensure that two
histidine residues in the correct conformation would be available for conjugation. Since histidine is
a natural amino acid, routine methods of site-directed mutagenesis were used to generate the IFN
variants from E. coli in soluble form at titres comparable to native IFN. PEGylation conversions ranged
from 28–39%. A single step puriﬁcation process gave essentially the pure PEG–IFN variant (>97% by RP-
HPLC) in high recovery with isolated yields ranging from 21–33%. The level of retained bioactivity was
strongly dependent on the site of PEG conjugation. The highest biological activity of 74% was retained
for the PEG10-106(HGHG)-IFN variant which is unprecedented for a PEGylated IFN. The His2-tag at
106(HGHG)-IFN is engineered at the ﬂexible loop most distant from IFN interaction with its dimeric
receptor. The biological activity for the PEG10-5(HGH)-IFN variant was determined to be 17% which is
comparable to other PEGylated IFN conjugates achieved at or near the N-terminus that have been
previously described. The lowest retained activity (10%) was reported for PEG10-120(HHH)-IFN which
was prepared as a negative control targeting a IFN site thought to be involved in receptor binding. The
presence of two histidines as a His2-tag to generate a site-selective target for bis-alkylating PEGylation is
a feasible approach for achieving site-selective PEGylation. The use of a His2-tag to strategically
engineer a conjugation site in a protein location can result in maximising the retention of the biological
activity following protein modiﬁcation.Introduction
The functionality and eﬃcacy of therapeutic proteins can be
increased by the covalent conjugation of drugs, probes and
polymers (e.g. antibody drug conjugates (ADCs) and PEGyla-
tion). Most proteins will have regions and sites in their structure
where conjugation can result in optimal stability, activity, and
pharmacokinetics.1–3 Computational strategies are being used
to identify sites in the protein structure to predict the impact of
PEGylation.1 Site-selective conjugation generally requires bothllege London, 29-39 Brunswick Square,
hini@ucl.ac.uk
aham, Cambridge CB22 3AT, UK
tion (ESI) available. See DOI:
ited, Ash Road, Wrexham Industrial
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ath Road, SL1 4DX Slough, UK.
hemistry 2019(i) molecular engineering of the protein of interest to introduce
a conjugation site at a dened location and (ii) a site-specic
conjugation technology.4
Many conjugation methods have been described5,6 and
some7–13 can be specic for an amino acid residue or a glycosyl
moiety. Cysteine incorporation into a protein as a site for
conjugation has been described in many preclinical studies14,15
including studies where large numbers of variants have been
designed to determine the best site for an unpaired cysteine.16
Introduction of an additional cysteine can cause scrambling of
the native disuldes, and protein dimerisation, oxidation, and
aggregation.17,18 The presence of an accessible cysteine for
conjugation can also cause protein aggregation during down-
stream processing by forming intermolecular disuldes. The
unpaired single cysteines engineered into a protein can also
be blocked for conjugation by cysteinylation and gluta-
thionylation, which are referred to as ‘cysteine capping’.19 These
oxidised forms of the added cysteine must be reduced before
conjugation can be conducted, which can oen be diﬃcult to
accomplish without reducing natural disulde bonds that mayChem. Sci., 2019, 10, 427–439 | 427
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View Article Onlinebe present in the protein. Incorporation of an unpaired cysteine
for conjugation is best utilised in proteins that do not have
a native disulde.
Site-selective conjugation can be achieved by the incorpora-
tion of noncanonical amino acids (ncAA), which are sometimes
referred to as non-natural amino acids (NNAAs).20–25 As with
cysteine incorporation, ncAA incorporation can be achieved by
addition or substitution of a single amino acid into the protein
of interest. ncAA incorporation is typically achieved by geneti-
cally reassigning a stop codon as a recognition site for an
engineered pair of tRNA and aminoacyl-tRNA synthetase that
incorporates the ncAA at the stop codon.26 However, protein
expression using stop codon reassignment can result in “leak
expression”27 and low yields of protein expression28 due to low
overall suppression eﬃciency dened as the percentage of stop
codon read-through, and due to mechanisms that degrade
mRNA29 containing premature stop codons, called nonsense
mediated mRNA decay. Strategies have been described1,26,30
such as using cell-free protein synthesis to address limitations31
for the specic incorporation of ncAAs.
ncAAs have side chains (e.g. keto, azide or alkyne) with
orthogonal reactivity to native amino acids.20–25 Conjugation
conversions and yields with ncAA modied proteins can be
high32 depending on many factors including reagent stoichi-
ometry and the presence of catalysts (e.g. copper). Orthogonal
reaction conditions must be suitable for protein modication.
For example, the use of copper in click approaches can be
challenging due to toxicity33 and can cause protein misfolding,
aggregation and degradation.34 Copper readily complexes to
proteins and is the basis for quantication assays, so it is not
clear why there has been so much eﬀort to use copper in
conjugation reactions with proteins.
Strain-promoted azide alkyne cycloadditions (SPACC) is one
alternative to avoiding copper. However, hydrophobicity caused
by conjugation linker moieties35 or due to surface accessible
ncAAs can cause non-specic protein binding.36 Although the
impact of hydrophobicity will be less at the site of conjugation
for PEGylation applications, ADC hydrophobicity has also
long been recognised to cause accelerated clearance and
reduced eﬃcacy.37,38 ADC hydrophobicity is also caused by
linker–drug structure and the drug–antibody ratio (i.e. drug
loading). Strategies have been described to solve the chal-
lenges caused by hydrophobicity to (i) reduce non-specic
binding in azide alkyne cycloadditions39,40 and (ii) optimise
ADC development.41,42
Increased conjugation selectivity can also be accomplished
by removal of amino acid residues that undergo competitive
conjugation. This strategy was followed for the development of
PEGvisomant,43 which is a growth hormone antagonist. Lysine
residues were substituted to arginine to remove PEGylation
sites that caused unacceptable reduction in biological activity.
Lysine depletion approaches have been used to promote
N-terminal44 or to have a single lysine residue remaining to
promote site-selected conjugation.44–46 Use of lysine depletion
methods is challenging because lysines are usually abundant47
and are necessary for protein activity.45,48–50 Strategies continue
to be developed for lysine specic conjugation.51428 | Chem. Sci., 2019, 10, 427–439We have found that the PEG-bis-sulfones 1 can undergo site-
specic bis-alkylation with the two thiols from a native disulde
bond in a protein (Fig. 1A and B).52,53 The bis-sulfone 1
undergoes elimination of a toluene sulnic acid (e.g. 2) to the
mono-sulfone 3 which is then capable of undergoing
a sequence of addition–elimination reactions to site-specically
modify the protein by re-bridging a reduced disulde with
a three carbon bridge attached to PEG. Other bridging reagents
have been described,54–57 and we have continued to examine
reagents based on the PEG-bis-sulfone 1 due to the simplicity of
their preparation and their practical application to prepare
ADCs58–60 and antibody mimetics.61–63
We have also found that the PEG bis- and mono-sulfones
(1 and 3) can site-specically undergo conjugation to the
histidines in a C- or N-terminal histidine tag (His-tag)
(Fig. 1C)64 without need of metal chelation. His-tags are
a contiguous sequence of histidines (e.g. six histidines, His6-
tag), which are widely used in a broad range of applications in
protein science and enable eﬀective purication and can also
increase protein expression yields.65,66 His-tags are usually
placed at a C- or N-terminus of a protein where oen one or
both of these regions of a protein do not adversely compete
with protein function, e.g. binding or activity. Our reasoning
was that PEGylation at a terminal His-tag would display
higher activity, which indeed is what was observed with
interferon a2-a and a domain antibody.64 Another way to
target His-tags for conjugation is to use reagents chelated to
nickel or zinc which can then complex to the imidazoles in
a His-tag on a protein. Applications tend to be for protein
labeling and immobilisation.67–69 Covalent bonds can be
formed aer complexation by subsequent reaction by other
functionality on the reagent.70,71
During our studies of His-tag PEGylation,64 preliminary
experiments were also conducted with a small peptide called
chemerin-9 peptide (149-YFPGQFAFS-157). Varying numbers of
histidines (e.g. two, four or six) and a histidine–glycine tag
(HGHGHG) were appended to the C-terminus of the peptide.
Chemerin-9 peptide does not contain any lysines and PEGyla-
tion was only observed when histidines were added to the
peptide. We now examine the site-selective conjugation of PEG-
mono-sulfone 3 to a truncated histidine tag comprised of 2
histidines (His2-tag) engineered into a protein that also has
several lysine residues. Compared to a 6 histidine tag (His6-tag),
a His2-tag could be positioned at more locations within the
protein for site-selective conjugation while ensuring protein
function can be maintained.
Most therapeutic proteins do not have contiguous histi-
dines in their sequence, although some proteins are known
to have clusters of histidines at their surface.72 While histi-
dine is a relatively rare amino acid in proteins73 using bis-
alkylation to target two histidines that are close together
rather than a strategy to target one histidine will avoid the
problem of competitive conjugation to other histidines in
the protein of interest. There are three natural histidines and
11 lysine residues in interferon a2, none of which were
conjugated when there was a N-terminal His-tag on inter-
feron a2.64This journal is © The Royal Society of Chemistry 2019
Fig. 1 (A) Chemical structure of the PEG-bis-sulfone 1 and formation of the PEG-mono-sulfone reagent 3 generated after elimination of toluene
sulﬁnic acid 2; (B) both PEG-bis- and mono-sulfone reagents (1 and 3) can undergo site-speciﬁc bis-alkylation with the two cysteine thiols from
a native disulﬁde in a protein achieving disulﬁde-bridging PEGylation;52 (C) both reagents (1 and 3) also undergo conjugation to the histidines in
a C- or N-terminal histidine tag (His-tag);64 (D) herein we investigated site-selective bis-alkylation conjugation at a His2-tag engineered at
a selected site along the protein mainchain; (E) mechanism for conjugation by bis-alkylation at a His–Gly–His tag by a sequence of addition–
elimination reactions to the initial conjugate 4. Carbonyl reduction to give 5 stops de-PEGylation by preventing retro-Michael reactions.
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View Article OnlineHistidines have a lower pKa than other nucleophilic resi-
dues in a protein, i.e., lysine and arginine, so at mildly acidic
pH (5–6) they may not be protonated, so can be reactive.
Conjugation by bis-alkylation using reagents such as 1 and 3
can be equilibrium controlled via an addition–elimination
reaction that is reliant on the Michael reaction. Covalent
conjugation occurs with 2 amino acids close in space (e.g.
the two cysteine thiols from a disulde53 or two histidines in
a C- or N-terminal his-tag64). Conjugation to two lysine amino
nucleophiles in slightly acidic conditions is not favoured for
reagents 1 and 3 when there are cysteine thiols or histidine
imidazoles present. Therefore, using 2 closely placed histi-
dines in interferon a2 (Fig. 1D and E) may provide an alter-
native method for achieving site-selective conjugation
compared to, for example, (i) adding an unpaired cysteine to
a protein with existing disuldes and (ii) incorporating ncAAs,
which have been described for interferon a2.15,74
The aim of the study described herein was to determine if
site-selected bis-alkylation conjugation could be accomplished
with a two histidine tag (His2-tag) placed within the primary
sequence of interferon a2-a to give a PEGylated interferon with
a higher biological activity than has been observed previously
for PEGylated interferon a2.This journal is © The Royal Society of Chemistry 2019Results and discussion
Preparation of truncated N-terminal His-tag IFN analogues
Interferons are a group of naturally occurring cytokines
produced in vertebrates in response to a viral infection.75
Cytokines are a broad group of proteins that have clinical
relevance,76,77 but quickly clear from circulation, so several
cytokines that have been approved for clinical use have also
been PEGylated.
Interferons are a key component of the innate immune
response and are used clinically to treat a wide range of
conditions including viral infections, malignancies and
multiple sclerosis. There are three types of interferon (I, II and
III), and type-I interferons that are used clinically include
interferon a and b. There are at least 13 diﬀerent human
interferon a proteins, all which have 166 amino acids except for
interferon a2 which has 165 amino acids due to a deletion at
position 44. Like many cytokines, interferon is a helical bundle
protein that has a cluster of ve a-helices, four of which are
arranged to form a le handed helix bundle motif (helices A, B,
C and E).78–80 Between helix A and B is a loop of 30 residues.
Initial experiments were conducted to determine if less
than eight histidine residues at the N-terminus of interferonChem. Sci., 2019, 10, 427–439 | 429
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View Article Onlinea2-a could undergo conjugation with PEG10-mono-sulfone 3 in
conditions where native interferon a2-a was not PEGylated. The
reagent 3 was derived from a PEG with a molecular weight of
10 kDa, so is abbreviated PEG10-mono-sulfone 3. Interferon a2-a
will herein be abbreviated to ‘IFN’.
It was rst necessary to determine if a truncated N-terminal
His2-tag IFN could undergo conjugation in conditions where
native IFN did not undergo conjugation. Selective conjugation
was thought more probable to occur in slightly acidic condi-
tions to avoid lysine conjugation, so reactions were conducted
with the PEG10-mono-sulfone 3 rather than PEG10-bis-sulfone 1.
The use of the PEG mono-sulfone 3 undergoes conjugation
directly without the need for elimination of the rst molecule of
toluene sulnic acid 2 (Fig. 1A). The elimination of toluene
sulnic acid 2 is much slower at acidic pH values than at neutral
and basic pH values.53
Although it was not clear which IFN variants would be
expressed, we sought to prepare four diﬀerent histidine-
truncated tags (ESI†). The rst two IFN variants were fused
with two or four contiguous histidines followed by glycines. Tag
1 (HHGGGG-IFN) and Tag 2 (HHHHGG-IFN) (Fig. 2A) were
followed by glycines to make up a 6-amino acid tag analogous to
a typical His6-tag commonly used in protein expression studies.
The remaining two N-terminal IFN variants were prepared with
a glycine separating the histidine residues: Tag 3 (HGHGGGG-
IFN) and Tag 4 (HGHGHG-IFN) (Fig. 2A). Flexible protein
inter-domains are rich in glycine residues.81 Our premise was
that a His2-tag separated by a glycine would result in the exi-
bility needed to ensure the histidines would be positioned to
achieve selective and eﬃcient conjugation.
Initial expression experiments were not successful using the
pET1010/D-TOPO® vector which had been used to prepare
N-terminal 8-histidine tagged IFN (H8-IFN).64 We then examinedFig. 2 (A) Four N-terminal histidine tags were designed and fused to I
undergo selective conjugation with PEG10-mono-sulfone 3; (B) SDS–PAG
fusion proteins that were isolated and then digested to separate the SUM
puriﬁed N-terminal IFN variants; (D) purities of the N-terminal IFN var
(HHHHGG-IFN) variant could be isolated, so was not used in the conjugat
4) used for conjugation studies displayed equivalent activity compared t
430 | Chem. Sci., 2019, 10, 427–439IFN variants that were expressed as a fusion protein with the
SUMO-tag using the Champion™ pET SUMO Expression system
previously used to produce consensus interferon.82 The SUMO
fusion of the four N-terminally tagged IFN variants were expressed
on a 0.5 L scale using the SHuﬄe® E. coli expression strain.
The SUMO fusions of the N-terminally tagged IFN variants
were expressed successfully in soluble form and were present in
the supernatant fraction (ESI Fig. S1†). The SUMO fusion
partner contains a His6-tag that allows aﬃnity purication of
the fusion protein prior to digestion needed to release the
desired his-tagged IFN variant. Each SUMO–IFN variant was
thus puried from the soluble fraction by immobilised metal
aﬃnity chromatography (IMAC) followed by digestion to
remove the SUMO fusion partner (Fig. 2B). A second IMAC
purication step was used as a negative purication step to
separate the cleaved SUMO partner and yield the puried IFN
variants (Fig. 2C). Purity of isolated IFN was conrmed by
RP-HPLC (Fig. 2D, RP-HPLC are shown in the ESI†).
The Tag 2 variant (HHHHGG-IFN) with four contiguous
histidine residues was biologically active (Table 1) but was
diﬃcult to purify at high enough scale from the SUMO protein,
which contains six contiguous histidine residues. Since the aim
of these experiments was to select a His2-tag if possible, it was
decided that initial conjugation studies would be conducted
using the other three His-tagged IFN variants: (i) Tag 1
(HHGGGG-IFN), (ii) Tag 3 (HGHGGGG-IFN) and (iii) Tag 4
(HGHGHG-IFN). These three IFN variants all displayed
comparable activity to the interferon a-2a NIBSC standard in the
A549/EMCV antiviral in vitro biological assay (Fig. 2E, Table 1).
Conjugation to the truncated N-terminal His-tag IFN variants
PEG conjugation studies with the three His-tagged IFN variants
(Tags 1, 3 and 4) were conducted using PEG10-mono-sulfone 3.FN to examine if diﬀerent conﬁgurations of histidine residues would
E gels (colloidal blue) of the N-terminally histidine tagged IFN–SUMO
O protein from the IFN variant; (C) SDS–PAGE gel (colloidal blue) of the
iants as determined by RP-HPLC. Only small amounts of the Tag 2
ion studies. (E) The three N-terminally tagged IFN variants (Tags 1, 3 and
o native IFN.
This journal is © The Royal Society of Chemistry 2019
Table 1 Antiviral activity of N-terminally tagged IFN variants conﬁrmed that fusion of a histidine–glycine tag to the N-terminus does not impact
on IFN activity
Sample
Specic activity calculated to NIBSC IFNa-2a [MIU per mg]
IFN
Tag 1 Tag 2 Tag 3 Tag 4
HHGGGG-IFN HHHHGG-IFN HGHGGG-IFN HGHGHG-IFN
n n ¼ 3 n ¼ 5 n ¼ 5 n ¼ 5 n ¼ 5
MEAN 254.2 228.5 216.7 242.4 218.4
SEM 34.5 23.2 18.5 31.4 51.4
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View Article OnlineThe 10 kDa molecular weight PEG is comparable to that used in
the clinic for PEG-Intron® (12.5 kDa PEG) and many prior
studies indicate that a 10 kDa PEG was suﬃciently large
enough83 to surpass the molecular weight threshold needed to
sterically shield the IFN to reduce its biological activity.
Native IFN64 was used as a control for these conjugation
studies. When the conjugation reaction was conducted at pH
5.0 at a protein concentration of 1 mg mL1 and 5 eq. of PEG10-
mono-sulfone 3 for an incubation period of 16 h at 20 C, the
conversion to the mono-PEGylated species ranged from 29% to
35% for the three IFN variants (Tags 1, 3 and 4) whilst only 7%
PEGylation was observed for the non-His-tagged IFN (Fig. 3A
and B).
The HGHGHG-IFN variant (Tag 4) with three histidine resi-
dues did show an increased tendency to form di- and tri-
PEGylated products when 5 equivalents of PEG10-mono-
sulfone 3 was used in these conditions (i.e. incubated for 16 h
at 20 C). Multiple PEGylation is possible for the HGHGHG-IFN
variant between the three histidines and the terminal amine.
The HHGGGG and the HGHGGG-IFN variants with two histi-
dine residues generated little or no di-PEGylated product.
Increased protein concentration and PEG stoichiometry yielded
unacceptable amounts of multi-PEG conjugates (Fig. 3A).Fig. 3 PEG conjugation studies of truncated N-terminal His-tagged IFN
PEG10-mono-sulfone 3 ratios were screened and the conjugation reac
eﬀective conjugation at the histidine-tag was achievedwhen reactionwa
of PEG10-mono-sulfone 3. The conversion to the mono-PEGylated sp
PEGylation on native IFN. (A) SDS–PAGE gels (colloidal blue) showing t
PEGylation conversion rates using densitometry analysis for the conjuga
This journal is © The Royal Society of Chemistry 2019Previously with N-terminal octahistidine tagged IFN
(H8-IFN)64 we found no evidence of PEG conjugation except on
the His-tag suggesting histidine conjugation was faster at the
optimal conditions than at other sites on the protein, and that
once PEG was conjugated to the His-tag then it is possible that
steric eﬀects slowed the rate of non-specic conjugation.
Most optimised conjugation reactions require well dened
and mild reaction conditions that are conducive to maintaining
protein structure while achieving eﬃcient and selective conju-
gation. At commercial scale, the cost of the GMP conjugation
reagent is comparable or more expensive than the cost of the
protein. Scalability considerations require that reagent stoichi-
ometry, the amount of unmodied protein remaining aer
conjugation and the purication process used to isolate the
desired conjugate should all be taken into account. Isolation of
the desired conjugate from excess unmodied protein and
conjugation reagent can generally be conducted eﬀectively at
scale.
Reductive amination strategies which require imine forma-
tion followed by mild reduction aim to exploit a small pKa
diﬀerence of the N-terminal amine for conjugation compared to
the other amines in the protein. For PEG to be predominantly
conjugated at the N-terminal amine,84 a narrow set ofvariants (Tags 1, 3 and 4) and native IFN used as control. Protein to
tion was conducted for 16 h at 20 C. It was observed that the most
s conducted at pH 5.0 at a protein concentration of 1 mgmL1 and 5 eq.
ecies ranged from 29–35% for the three IFN variants, while only 7%
he PEG-conjugation reaction mixtures screened and (B) estimates of
tion conducted with protein concentrations of 1.0 and 2.5 mg mL1.
Chem. Sci., 2019, 10, 427–439 | 431
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View Article Onlineconditions that are protein dependent is required. Exploiting
a slight diﬀerence in the pKa of a single N-terminal amino acid
to achieve high yielding and homogeneous imine formation in
an aqueous medium is not possible with low reagent stoichi-
ometry or complete site specicity.85,86 Several strategies have
been described to direct conjugation to the N-terminus of
a protein to address the inherent limitations of reductive ami-
nation using PEG aldehyde reagents.13,64,87
The data with the truncated N-terminal histidine tagged IFN
variants (Fig. 3A and B) indicate that the best mono-PEGylation
conditions were to incubate PEG10-mono-sulfone 3 (5 eq.) with
the IFN variant at 1 mg mL1 for 16 h at 20 C (pH 5.0). Using
these conditions, all three of the IFN histidine variants resulted
in conjugation broadly comparable to that previously observed
with an N-terminal H8-IFN.64 Purication of the N-terminal
PEG–IFN conjugate was also easy to conduct. A single pair of
histidines separated by a glycine, e.g. HGH, was then incorpo-
rated within the IFN mainchain as a site-selective conjugation
location.Site selection on IFN for histidine conjugation
Sites to incorporate an internal His-tag for conjugation were
considered based on the published ndings of IFN binding
interactions with its dimeric receptor and the in vitro biological
activities of isolated PEG-positional isomers.88,89 IFN exerts its
biological activity through binding to the specic cell surface
receptors.90 Features of the IFN structure and its interaction
with cell membrane receptors have been described and key
residues mediating these interactions have been determined.91
Type 1 IFNs bind to a heterodimeric cell surface receptor
(IFNAR1 and IFNAR2).91–95 The amino acid sequences 29–35, 78–
95 and 123–140 are thought to bind to IFNAR1 and IFNAR2.91,94.
The two main clinically used PEGylated interferon products
(PEG-Intron® and Pegasys®) are produced with PEGylation
reagents that undergo non-specic conjugation on interferon a2
proteins that diﬀer by one amino acid. Pegasys® is produced
from interferon a2-a (lysine at position 23) and PEG-Intron® is
produced from interferon a2-b (arginine at position 23).Fig. 4 The IFN variants with an incorporated histidine conjugation tag (sh
IFN binding interactions with its receptor and in vivo biological activities
432 | Chem. Sci., 2019, 10, 427–439PEG-Intron® is a 12 kDa PEG conjugate of interferon a2-b
derived from a linear PEGylation reagent functionalised with an
N-hydroxy-succinimide (NHS) active ester that undergoes non-
selective acylation with protein nucleophiles (e.g. terminal
amine, lysine amines). There are at least 13 mono-PEGylated
interferon a2-b positional isomers in PEG-Intron® with PEG
conjugated at lysine, serine and histidine residues, and at the N
terminus (Cys1).88,96 Most of the observed activity is from the
positional isomer where PEG is conjugated to His34 (or H34).97
Reaction of an NHS ester with the histidine imidazole side
chain results in the formation of a hydrolytically labile carbonyl
imidazolide. The H34 positional isomer is the most hydrolyti-
cally labile PEG positional isomer,97 so the observed activity of
37% for H34 positional isomer is likely due to the presence of
de-PEGylated, unmodied interferon a2-b. The in vitro antiviral
activity of the positional isomer at the amine terminus is13%,
however the activities of the other positional isomers that have
been described are much lower (<10%).
Pegasys® is made using a lysine-derived branched PEG
reagent with two 20 kDa PEG molecules linked via urethanes to
the two lysine amines. An NHS active ester at the lysine
carboxylate functions as the protein conjugating moiety which
undergoes non-selective acylation with protein nucleophiles.
Hydrolysis of NHS functionalised PEG reagents is reported to be
competitive at pH values where amine conjugation can occur
(e.g. pH 7.5–8.0).98 While an excess of 5 equivalents has been
claimed to give a 45% conversion tomono-PEGylated IFN a-2a,99
other studies indicate the need to use a greater excess of NHS
PEGylation reagents (10 eq.).100 Pegasys® comprises at least
nine bioactive positional isomers, with four major isomers
PEGylated at the lysine residues at positions 31, 21, 131 and
134.89,101,102 The in vitro activities of the positional isomers range
from 2% to 12%.
Five diﬀerent IFN variants with internal His-tags (or
PEG-tags) were thus prepared (Fig. 4, Table 2, ESI†). The
5(HGH)-IFN variant was designed by engineering Q5H and T6G
substitutions. One of the three natural histidine residues
present within IFN is located at position 7, therefore this amino
acid was not substituted. The resulting 5(HGH) conjugation tagown in red) were rationally designed based on the published ﬁndings on
of the isolated PEG-positional isomers from marketed products.
This journal is © The Royal Society of Chemistry 2019
Table 2 Detailed description of the internal His-tagged IFN variants
showing the localisation of His-tag insertion, sequence of the His-tag
and native amino acids that were replaced
IFN PEG-tag location His-tag sequence
Original IFN
amino acids
5(HGH)-IFN 5 HGH QTH
34(HGHG)-IFN 34 HGHG HDFG
106(HGHG)-IFN 106 HGHG T-ET
120(HHH)-IFN 120 HHH RKY
134(HGHG)-IFN 134 HGHG K-YS
Fig. 5 (A) SDS–PAGE gels (colloidal blue) of the ﬁve internal His-
tagged IFN variants which had been expressed as IFN–SUMO-fusion
proteins (colloidal blue detection). Proteolytic digestion with SUMO
protease followed by IMAC puriﬁcation yielded the designed IFN
variants; (B) all of the histidine IFN variants were puriﬁed to high purity
as determined by RP-HPLC; (C) antiviral activity showed that three
histidine IFN variants had similar activity to native IFN, whereas the
34(HGH)-IFN variant was low (5%) compared to native IFN. The
reduction in antiviral activity was not unexpected as the natural
histidine located in position 34 in IFN is known to be important for IFN
biological activity.
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View Article Onlineis located within a short, exible and solvent accessible loop in
close proximity to the N-terminus of the protein. PEGylation of
5(HGH)-IFN allows comparison with the N-terminal H8-IFN
conjugates previously described64 and the N-terminal
PEG-Intron® positional isomer.
The 34(HGH)-IFN variant was prepared to evaluate if we
could conjugate a PEG at the His34 (H34) site to compare with
PEG-Intron®. The tag was incorporated through D35G and
F36H substitutions. H34 is located on the AB loop and is
thought to be involved in binding to the IFN receptor, thus it
was anticipated that signicant reduction of biological activity
of native IFN would be observed.
The 106(HGHG)-IFN variant was prepared as this position is
located within a exible loop that is thought not to be involved
with receptor binding. While glycosylation is rare among native
human interferons, it is known that T106 can be O-glycosylated
in interferon a2-b.103,104
Although IFN has two disuldes (C1–C98 and C29–C138),
a study was conducted to insert a free cysteine at position 111
which is at the beginning of the D a-helix aer the proline
residue in this region.15 This cysteine IFN variant was PEGylated
with maleimide PEG reagents and displayed comparable in vitro
activity to PEG-Intron® in the Daudi cell growth inhibition
assay. There are no reported PEG positional isomers at posi-
tions 99–109 in PEG-Intron® or PEGasys® due to the absence of
nucleophilic amino acids in this region of the protein.88,89
The 106(HGHG)-IFN variant was created by making T106H,
E107G and T108H substitutions. An additional G108 was
inserted to allow more exibility within the conjugation tag
because there is a following proline in the IFN sequence.
Proline restricts free rotation and typically appears on the
surface of proteins while introducing a b-turn in the amino
acid sequence.
Another IFN variant that was prepared is 120(HHH)-IFN,
which was engineered with R120H, K121H and Y122H substi-
tutions in the D a-helix. This tag is present in the D-helix which
is solvent-exposed, but is less exible compared to the loop
regions where other IFN tags are located. The PEG positional
isomer at lysine 121 (K121) in PEG-Intron® and PEGasys®
displays <10% activity,88,89 so the 120(HHH)-IFN variant was
prepared as a negative control. Three contiguous histidine
residues (HHH) were used in this tag rather than a HGH tag to
account for the lack of exibility in the D-helix and to allow the
imidazole rings to adopt a conformation for bis-alkylation
conjugation.This journal is © The Royal Society of Chemistry 2019The nal tagged IFN variant, 134(HGHG)-IFN, was created
using K134H, Y135G and S136H substitutions and insertion of
additional glycine. The additional glycine was inserted because
of the following proline residue in the sequence. The
134(HGHG) tag was created as another negative control to
compare against the K134 positional isomer described during
the development of Pegasys®,89which had displayed low activity
(<10%; 1358  46 U mg1).
Expression of the ve internal His-tagged IFN variants was
conducted using the SUMO system using SHuﬄe® E. coli strain
(ESI†). No soluble expression was observed for 134(HGH)-IFN
and this variant appeared to be present as insoluble protein
aggregates at the top of SDS–PAGE well (Fig. S2†). This variant
contains a tag in the binding region of IFN and was not expected
to display increased in vitro antiviral activity once PEGylated
over the other PEGylated IFN positional isomers described
herein. No further attempts were made to express this protein.
Fermentations (1 L) were conducted with the four remaining
variants to give 90–110 mg of the SUMO–IFN protein per variant
(ESI†). Each IFN variant was obtained aer SUMO digestion and
isolated by a sequential IMAC–anion exchange purication
process. IMAC retained the SUMO fusion partner and the SUMO
protease while allowing the elution of the IFN variants onto an
anionic ion exchange chromatography (IEC) column. Each
bound IFN variant was eluted at a concentration of1 mgmL1Chem. Sci., 2019, 10, 427–439 | 433
Chemical Science Edge Article
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
9 
O
ct
ob
er
 2
01
8.
 D
ow
nl
oa
de
d 
on
 1
/1
7/
20
19
 9
:2
4:
01
 A
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Onlineto be used for conjugation studies (Fig. 5A) (ESI†). The four IFN
variants were isolated in good purity (Fig. 5B, RP-HPLC are
shown in the ESI†).
The process of protein engineering and verication of
protein expression was shown to be straightforward and took
less than two weeks. All of the expressed IFN variants remained
soluble and stable following removal of the SUMO fusion
partner. The expression method that was used to obtain the IFN
variants did not require further optimisation from the method
established for expression of native IFN.82 The in vitro antiviral
activity of the four internal His-tagged IFN variants was deter-
mined using the A549/EMCV antiviral assay (Fig. 5C) using the
NIBSC standard for IFN as control. The specic activities of the
5(HGH)-IFN, 106(HGHG)-IFN and 120(HHH)-IFN variants were
similar to the NIBSC standard (Fig. 5C). The activity of the
34(HGH)-IFN variant was considerably lower (5% compared to
native IFN) so this variant was not used in subsequent conju-
gation studies. The 34(HGH)-IFN variant was produced to
compare with the H34 PEG positional isomer in PEG-Intron®.97
The reduced activity of 34(HGH)-IFN was not unexpected as theFig. 6 PEG conjugation studies were conducted with three of the intern
was used for conjugation with each IFN variant at 1 mg mL1. The con
conjugation conversions ranged between 28–39% and were similar to
conjugation: lane M protein markers, lane 1, the IFN variant used for PEGy
the left gel is stained with colloidal blue and the right gel is further stain
isolated from the crude conjugation reaction mixture using a single ion
determined by SDS–PAGE (silver stain) and by RP-HPLC (Fig. S3†); (D) s
phosphate, 150 mM NaCl, pH 7.4 buﬀer with each PEG–IFN conjugate a
were stable to de-PEGylation with no evidence of free IFN being detect
week 1, lane 2, week 2, lane 3, week 3, lane 4, week 4 and lane 5, native
434 | Chem. Sci., 2019, 10, 427–439natural histidine located in position 34 in IFN is known to be
important for biological activity.96,105–107Site-selective conjugation studies
Conjugation with PEG10-mono-sulfone 3 was examined with the
three remaining IFN variants (Fig. 6A) using the conditions
determined previously for the N-terminal truncated His-tagged
IFNs (Fig. 3). The conjugation reactions were conducted with 5
molar equivalents of PEG10-mono-sulfone 3 and allowed to
incubate overnight at 20 C followed by analysis using SDS–
PAGE (Fig. 6B). Conversions to the mono-PEGylated conjugates
(28–39%) were similar to conversions observed during conju-
gation of the N-terminally His-tagged IFN variants (Fig. 3B).64
The stoichiometry of the PEG10-mono-sulfone 3 and the
conversions to the PEG–IFN conjugate also compare favourably
to other amine conjugation methods.99
Trace di-PEGylated product was sometimes observed by SDS–
PAGE and was readily removed during purication. Non-specic
PEGylation may have occurred in addition to PEGylation on theal His-tagged IFN variants (shown in A). PEG10-mono-sulfone 3 (5 eq.)
jugation reaction was conducted for 16 h at 20 C and the observed
the N-terminally tagged IFNs. (B) SDS–PAGE gels for each IFN variant
lation and lane 2, the PEGylation reaction mixture. For each IFN variant,
ed with barium iodide. (C) Puriﬁed mono-PEGylated IFN variants were
exchange puriﬁcation step to deliver a ﬁnal product in high purity as
tability studies were conducted for 4 weeks at 4 C in 50 mM sodium
t 0.2 mg mL1. All of the three site-selectively PEGylated IFN variants
ed with anti-IFN western blot analysis, lane M protein markers, lane 1,
IFN used as control.
This journal is © The Royal Society of Chemistry 2019
Fig. 7 (A) Antiviral activity showed that all three of the internally
histidine labelled PEG10-IFN variants were active, and that the level of
retained activity signiﬁcantly depends on the site of conjugation. (B)
Antiviral activity of the site-speciﬁcally PEGylated IFN variants revealed
that the site of PEG conjugation has signiﬁcant eﬀect on the level of
biological activity retained.
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View Article OnlineHis-tag. Prior to purication, the PEGylated IFN variants were
treated with sodium triacetoxyborohydride to reduce the aryl
ketone to prevent retro-Michael induced PEG deconjugation.64,108
Carbonyl reduction using a mild hydride reagent acts as a stabi-
lisation step and is comparable to the analogous process con-
ducted during reductive amination85,86,109–111 in the manufacture
of peglgrastim (Neulasta®).84 It has become evident even with
maleimides that it is necessary to conduct a post-conjugation
hydrolysis stabilisation step to avoid deconjugation.112–114
The mono-PEG conjugates were isolated from the crude reac-
tion mixtures by a single IEC step. Fractions containing the
majority of the 10 kDa mono-PEGylated IFN variants were
combined (typically 7mL) and then concentrated using a Vivaspin
concentrator to 1 mL. Determination of the protein concentration
for the three isolated PEG–IFN conjugates was accomplished
using microBCA protein assay to calculate the nal yields
(Table 3).
Analysis by SDS–PAGE (silver stain detection) revealed there
was no free IFN and RP-HPLC analysis indicated that the iso-
lated conjugates were produced in high purity (Fig. S3† and 6C).
No de-conjugation of PEG or free IFN was observed over a 28 day
period for conjugates stored at 4 C in 50 mM PBS, pH 7.4
(Fig. 6D, western blot analysis). Since SDS–PAGE analysis was
consistent throughout,32 no MALDI analysis of the conjugates
were conducted.
The fact that the mono-PEGylated IFN variant was by far the
major PEGylated species produced during each conjugation
reaction meant a simple one-step purication process based on
cation exchange chromatography was suﬃcient to purify the
desired PEG–IFN conjugate. The simple purication process
gave essentially the pure mono-PEGylated IFN variant (>97% by
RP-HPLC) in relatively high yields (based on conversion)
ranging from 21–33%. This is an excellent recovery for the
observed conjugation conversions (ranging from 28–39%).
All three PEG–IFN conjugates are biologically active (Fig. 7A
and B) in the A549/EMCV antiviral assay with specic activities
calculated against the NIBSC standard. The site of PEG conju-
gation inuences biological activity. As IFN binds to a hetero-
dimeric cell surface receptor, the conjugation site is important
to minimise competitive steric shielding eﬀects of the PEG with
IFN binding to its receptor. The conjugates displayed activity in
the following order: PEG10-106(HGHG)-IFN[ PEG10-5(HGH)-
IFN > PEG10-120(HHH)-IFN.
The decreased activity observed with PEG10-120(HHH)-IFN
(10%) is consistent with the activity observed for the PEG
positional isomers in PEG-Intron® and Pegasys® when PEG was
conjugated to the D a-helix at position 121. The activity was 9%
for PEG-Intron® and 2.2% for Pegasys®.88,89 The greaterTable 3 Final isolated yields for the site-selectively PEGylated IFN
variants
Conjugate Final yield [%]
PEG10-5(HGH)-IFN 25%
PEG10-106(HGHG)-IFN 33%
PEG10-120(HHH)-IFN 21%
This journal is © The Royal Society of Chemistry 2019reduction of bioactivity observed for Pegasys®may be due to the
conjugation having been done with a branched PEG reagent
(2  20 kDa PEG). The two separate PEG molecules, though
hinged, appear to cause greater steric shielding of the receptor
interaction site on IFN than a single linear PEG molecule.
The 17% activity of the PEG10-5(HGH)-IFN variant is similar
to that of the N-terminal H8-IFN that had previously been
PEGylated.64 Both PEG–IFN conjugates have the PEG near or at
the N-terminus of the IFN, which further supports theChem. Sci., 2019, 10, 427–439 | 435
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View Article Onlineimportance of the conjugation site on biological activity. Similar
activity of 10–16% was observed with a IFN variant with cysteine
inserted at position 5 for conjugates derived from PEG reagents
with molecular weights ranging from 10–40 kDa.15
The activity of the PEG10-106(HGHG)-IFN variant was similar to
that of the un-PEGylated 106(HGHG)-IFN parent protein (5.0 
0.3 pg mL1 vs. 3.8  0.6 pg mL1). PEG10-106(HGHG)-IFN dis-
played an exceptionally high activity of 74% relative to the unPE-
Gylated protein. The conjugation site in the 106(HGHG)-IFN
variant is located away from known receptor binding sites in
a exible and solvent accessible loop, which makes it possible for
retaining most of the bioactivity aer PEGylation. This level of
antiviral activity for a stable interferon PEG conjugate is unprece-
dented. The PEG10-106(HGHG)-IFN example demonstrates that
aHis2-tag can serve as a selective site for bis-alkylation conjugation.
Conclusions
Interferon a2-a variants were engineered with histidine conju-
gation tags. In most cases two histidines were separated by
a glycine (e.g.HGH) and this internal His-tag was placed at both
the N-terminus and at diﬀerent locations within the protein. We
have termed these internal His-tags ‘PEG-tags’. Bis-alkylation
PEGylation was used to give conjugates that displayed in vitro
antiviral activity that was dependent on the site of the PEG-tag.
PEGylation was conducted with bis-alkylation reagent 3 derived
from PEG with a molecular weight of 10 kDa.
Since histidine is a natural amino acid, it was possible to use
routine methods of site-directed mutagenesis to make the IFN
variants which were expressed in soluble form to give similar
titres obtained for native IFN. PEGylation conversions ranged
from 28–39% and a single step purication process gave
essentially the pure PEG–IFN variant (>97% by RP-HPLC) in
high recovery with isolated yields ranging from 21–33%.
The level of retained bioactivity was strongly dependent on
the site of PEG conjugation. The highest biological activity of
74% was retained for the PEG10-106(HGHG)-IFN which is
unprecedented for a PEGylated IFN. The His2-tag was placed at
a location in IFN where it was expected there would be minimal
interference of PEG during binding with the interferon recep-
tors. The biological activity for the PEG10-5(HGH)-IFN variant
was 17% which is comparable to other PEGylated IFN conju-
gates at or near the N-terminus that have been described in the
literature. The lowest retained activity (10%) was for PEG10-
120(HHH)-IFN which was prepared as a negative control as this
IFN variant was thought to be involved in receptor binding.
The presence of two histidines in PEG-tags to generate
a target for bis-alkylating PEGylation is a feasible approach for
site-selective PEGylation. The use of a PEG-tag strategically
placed in a protein can result in maximising the retention of the
biological activity aer protein modication.
Experimental
Preparation of PEG10-mono-sulfone 3
The PEG mono-sulfone 3 derived from 10 kDa PEG was used in
these studies. The PEG bis-sulfone 1 was rst prepared115 and436 | Chem. Sci., 2019, 10, 427–439was then incubated in 50 mM sodium phosphate buﬀer, pH 7.4,
2 mM EDTA, 150 mM NaCl at concentration of 10 mg mL1 for
a period of 6 h at 37 C to provide the PEG mono-sulfone 3.Site-selective PEGylation of IFN
Conjugation reactions were conducted on 1 mg scale of each IFN
variant. The IFN proteins: (i) 5(HGH)-IFN (1.5 mg mL1; 2 mL in
20 mM Tris, pH 8.0), (ii) 106(HGHG)-IFN (1.7 mg mL1; 2 mL in
20 mM Tris, pH 8.0) and (iii) 120(HHH)-IFN (1.6 mg mL1; 2 mL
in 20 mM Tris, pH 8.0) were buﬀer exchange to an acetate-based
PEGylation buﬀer (50 mM sodium acetate, pH 5.0 supplemented
with 35 mMhydroquinone). Buﬀer exchange was conducted using
a PD-10 desalting column (load: 2.5mL) and eluted in 3.5mL. The
protein concentration determined by absorbancemeasurement at
280 nm were around 0.9 mg mL1 for all samples (0.9 mg mL1
for 5(HGH)-IFN; 0.92 mg mL1 for 106(HGHG)-IFN and
0.9 mg mL1 for 120(HHH)-IFN: 0.9 mg mL1). The PEG mono-
sulfone 3 prepared at 10 mg mL1 was then added to each reac-
tion mixture using 5 molar equivalents: 226 mL for 5(HGH)-IFN
231 mL for 106(HGHG)-IFN; and 225 mL for 120(HHH)-IFN. The
conjugation reaction was allowed to incubate for 16 h at 20 C and
then the reaction mixtures were treated with 25 mM sodium tri-
acetoxyborohydride (19 mg) which was added to the reaction
mixture as a solid. The reaction mixture was allowed to incubate
for 45 min on ice. This sequence of adding sodium triacetoxy-
borohydride and 45 min incubation was repeated twice.
The reaction mixture was then buﬀer exchanged into 50 mM
sodium acetate, pH 4.0, using a pre-equilibrated PD-10 desalt-
ing column as previously described64 by loading 2.5 mL and
eluting with 3.5 mL. The PD-10 column was again equilibrated
with fresh buﬀer prior to the remaining 1.1 mL of reaction
mixture being loaded, followed by addition of 1.4 mL of 50 mM
sodium acetate, pH 4.0. The sample was then eluted with 3.5mL
of 50 mM sodium acetate, pH 4.0. The total volume of 7.5 mL of
buﬀer exchanged reaction mixture was collected and subjected
to ion exchange purication.
Cation exchange purication was performed on aMacroTrap
SP HP (5 mL) column operated on an A¨KTAprime™ system. The
column was rstly equilibrated with 30 mL of 50 mM sodium
acetate, pH 4.0 (buﬀer A), followed by load of the PEGylation
reaction mixture (7.5 mL). The ow-through was collected and
the column was washed with 15 mL of buﬀer A to remove any
residual PEG reagent. Subsequently, the column was washed
with an increasing concentration of NaCl by applying a gradient
elution of 50 mM sodium acetate, pH 4.0, 1 M NaCl (buﬀer B)
from 0% to 100% typically over 30 min at 1 mLmin1. Fractions
containing the desired product of the mono-PEGylated IFN
conjugate from each variant were combined and concentrated
to 1.0 mL using a Vivaspin centrifugal concentrator (MWCO
10 000, centrifuged at 3000g at 4 C).Conﬂicts of interest
JWC is an employee of Abzena. KP, EL and RT no longer are
employees of Abzena. SB was a co-founder of PolyTherics,
a subsidiary of Abzena, but is not aﬃliated with either company.This journal is © The Royal Society of Chemistry 2019
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